2023
Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions
2022
Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment
Gunstad J, Disabato D, Shrestha R, Sanborn V, Mistler CB, Copenhaver MM. Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment. Journal Of Addictive Diseases 2022, 41: 120-127. PMID: 35615880, PMCID: PMC9699904, DOI: 10.1080/10550887.2022.2080626.Peer-Reviewed Original ResearchConceptsLatent profile analysisNeurocognitive dysfunctionBrief inventoryNeuro-cognitive profileNeuro-cognitive impairmentSelf-reported neurocognitive symptomsProfile analysisOpioid-dependent patientsOpioid use disorderTreatment outcomesNeurocognitive impairmentDrug treatment outcomesMultiple domainsTreatment programUse disordersIntervention strategiesIndividual treatment needsNeurocognitive symptomsDrug treatment settingsTreatment settingsMethadone maintenance treatment programAccommodation strategiesModerate concernMaintenance treatment programOptimal treatment outcomes
2018
Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment
Shrestha R, Copenhaver M. Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. Frontiers In Public Health 2018, 6: 195. PMID: 30062091, PMCID: PMC6054971, DOI: 10.3389/fpubh.2018.00195.Peer-Reviewed Original ResearchPre-exposure prophylaxisPrEP adherenceHIV preventionHigh-risk PWUDSubstance abuse treatment settingsUse of PrEPHigh-risk peopleHIV risk behaviorsHIV prevention approachesPrEP servicesDaily dosingPrEP useHigh adherenceDepth semi-structured qualitative interviewsSemi-structured qualitative interviewsTreatment settingsPocket costsRisk behaviorsDisclosure statusPrEPAdherencePrevention approachesProphylaxisPreliminary evidencePWUD
2017
Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populationsDeveloping an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research
Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Frontiers In Immunology 2017, 8: 561. PMID: 28553295, PMCID: PMC5425476, DOI: 10.3389/fimmu.2017.00561.Peer-Reviewed Original ResearchNeurocognitive impairmentHigh-risk drug usersBehavioral interventionsHigh-risk PWUDHIV prevention behavioral interventionBiobehavioral approachHIV risk reductionHIV prevention interventionsDrug treatment settingsFormative researchHIV prevention effortsTarget populationPrEP adherencePrEP uptakeRisk reduction outcomesHIV preventionDrug treatmentPrevention interventionsFocus groupsTreatment settingsDrug usersRecovery programStructured focus groupsRisk behaviorsTarget population membersInterest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program
Shrestha R, Karki P, Copenhaver M. Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program. AIDS Care 2017, 29: 1144-1148. PMID: 28478706, PMCID: PMC6081193, DOI: 10.1080/09540121.2017.1325439.Peer-Reviewed Original ResearchConceptsHigh-risk PWUDMethadone maintenance programHIV preventionMedication remindersHIV risk reduction informationRisk behaviorsSex-related risk behaviorsHigh-risk drug usersMHealth technologiesHIV prevention toolHIV risk reductionHIV prevention approachesHIV risk behaviorsDrug treatment settingsRisk Behavior AssessmentHIV prevention effortsHIV-negative PWUDUse of mHealthNew intervention strategiesDepressive symptomsTreatment settingsDrug usersHealthcare providersMultivariate analysisPrevention efforts
2015
A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description
Shrestha R, Krishnan A, Altice FL, Copenhaver M. A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description. Contemporary Clinical Trials 2015, 44: 95-102. PMID: 26253181, PMCID: PMC4744142, DOI: 10.1016/j.cct.2015.08.002.Peer-Reviewed Original ResearchEvidence-based interventionsHIV risk behaviorsHolistic Health Recovery ProgramSex-related HIV risk behaviorsRisk behaviorsClinical settingCurrent HIV prevention effortsReal-world clinical settingHIV prevention behavioral interventionFormal cost-effectiveness analysisAntiretroviral therapy adherenceNon-inferiority trialHIV prevention effortsAddiction treatment settingsCommon clinical settingsCost-effective relativeCost-effectiveness analysisAddiction treatment programsTherapy adherenceTarget HIVTrial designHIVIntervention DescriptionTreatment settingsUnmet need